Therapy Name | CCT241533 + Rucaparib |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CCT241533 | CHK2 Inhibitor 5 | CCT241533 is an ATP-competitive inhibitor of CHK2, which enhances PARP inhibitor efficacy in cells lacking functional p53 (PMID: 21239475). | ||
Rucaparib | Rubraca | AG014699|PF-01367338|CO-388|AG14447 | PARP Inhibitor (Pan) 17 | Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use in ovarian cancer patients with deleterious somatic and/or germline BRCA mutations (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | colorectal cancer | not applicable | CCT241533 + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, CCT241533 enhanced the growth inhibition effect of Rubraca (rucaparib) in colorectal cancer cells in culture (PMID: 21239475). | 21239475 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|